Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation

Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation

Abstract INTRODUCTION Disease‐modifying therapies (DMTs) for Alzheimer's disease (AD) will increase diagnostic demand. A non‐invasive blood‐based biomarker (BBBM) test for detection of amyloid‐β pathology may reduce diagnostic barriers and facilitate DMT initiation. OBJECTIVE To explore heterog...

Full description

Bibliographic Details
Main Authors: Ivonne Suridjan, Wiesje M. van derFlier, Andreas U. Monsch, Nerida Burnie, Robert Baldor, Marwan Sabbagh, Josep Vilaseca, Dongming Cai, Margherita Carboni, James J. Lah
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
Alzheimer's disease
amyloid pathology
blood‐based biomarker
clinical practice
diagnosis
qualitative
Online Access:https://doi.org/10.1002/dad2.12508

Internet

https://doi.org/10.1002/dad2.12508

Similar Items